Epratuzumab

Generic Name: Epratuzumab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 205923-57-5

Unique Ingredient Identifier: 3062P60MH9

Background: Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.

Indication: Investigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Inotuzumab Ozogamicin in Pediatric Patients With Relapsed or Refractory B-Cell ALL

The review highlights inotuzumab ozogamicin's role in treating pediatric ALL, particularly R/R ALL, and evolving therapeutic options. It emphasizes the drug's FDA approval for pediatric patients, its efficacy in clinical trials, and ongoing research to improve ALL treatment strategies.

Related Clinical Trials:

A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy